11 completed, 2 active not recruiting, 2 not yet recruiting, 1 recruiting. 12 Phase 1, 2 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 12 | Completed 10, Active not recruiting 1, Not yet recruiting 1 |
| Phase 2 | 2 | Completed 1, Not yet recruiting 1 |
| Phase 3 | 2 | Active not recruiting 1, Recruiting 1 |
Follow MK-8527: new trials by email Literature Review of MK-8527 trials Research Report on MK-8527
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Study of Alimatravir (MK-8527) in Transgender (Trans) and Gender Diverse Individuals on Gender-affirming Hormone Therapy and at Low Likelihood of Human Immunodeficiency Virus (HIV)-1 Exposure (MK-8527-018) Alimatravir - HIV | Phase 2 | Not yet recruiting | Merck Sharp & Dohme LLC | 80 | 2026-10-29 | 2026-09-30 |
| A Clinical Trial of MK-8527 and Rifampin in Adult Participants With Latent Tuberculosis Infection (MK-8527-019) MK-8527, Rifampin - Human Immunodeficiency Virus (HIV), HIV Pre-Exposure Prophylaxis | Phase 1 | Not yet recruiting | Merck Sharp & Dohme LLC | 14 | 2026-09-01 | 2026-08-03 |
| A Clinical Study of MK-8527 in Healthy Participants (MK-8527-021) MK-8527, Probenecid, Itraconazole - Healthy | Phase 1 | Active not recruiting | Merck Sharp & Dohme LLC | 44 | 2026-06-30 | 2026-09-03 |
| A Clinical Trial in Healthy Participants to Study the Effect of a Single Dose of MK-8527 on Levels of Methadone (MK-8527-020) MK-8527, Methadone - Healthy | Phase 1 | Completed | Merck Sharp & Dohme LLC | 14 | 2026-05-22 | 2026-08-26 |
| A Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-010) MK-8527, Emtricitabine/tenofovir disoproxil (FTC/TDF), Placebo matched to MK-8527 - Human Immunodeficiency Virus (HIV), HIV Pre-Exposure Prophylaxis | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 4580 | 2025-11-10 | 2026-10-20 |
| A Clinical Study of MK-8527 in Participants With Mild and Moderate Hepatic Impairment (MK-8527-015) MK-8527 - Hepatic Impairment, Healthy Participants | Phase 1 | Completed | Merck Sharp & Dohme LLC | 18 | 2025-09-19 | 2026-02-27 |
| A Clinical Study of MK-8527 in Healthy Adult Participants (MK-8527-014) MK-8527, Moxifloxacin, Placebo - Healthy | Phase 1 | Completed | Merck Sharp & Dohme LLC | 42 | 2025-08-12 | 2026-01-29 |
| A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011) MK-8527, FTC/TDF, Placebo to MK-8527 - Human Immunodeficiency Virus (HIV), HIV Pre-Exposure Prophylaxis | Phase 3 | Active not recruiting | Merck Sharp & Dohme LLC | 4390 | 2025-07-31 | 2026-09-18 |
| A Study of Carbamazepine (CBZ) and MK-8527 in Healthy Adult Participants (MK-8527-012) MK-8527, CBZ - Healthy | Phase 1 | Completed | Merck Sharp & Dohme LLC | 16 | 2025-04-28 | 2025-07-29 |
| A Study of MK-8527 in Healthy Lactating Female Participants (MK-8527-009) MK-8527 - Healthy, HIV Pre-exposure Prophylaxis | Phase 1 | Completed | Merck Sharp & Dohme LLC | 13 | 2025-04-15 | 2026-04-16 |
| A Study of Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) and MK-8527 in Healthy Participants MK-8527, FTC/TDF - Healthy | Phase 1 | Completed | Merck Sharp & Dohme LLC | 20 | 2025-02-21 | 2025-06-27 |
| A Study of MK-8527 in Participants With Moderate and Severe Renal Impairment (MK-8527-008) MK-8527 - Renal Impairment | Phase 1 | Completed | Merck Sharp & Dohme LLC | 18 | 2024-06-20 | 2026-02-17 |
| Safety and Pharmacokinetic Study of Oral MK-8527 QM in Participants at Low-Risk for HIV-1 Infection (MK-8527-007) MK-8527, Placebo to MK-8527 - HIV, HIV Pre-exposure Prophylaxis | Phase 2 | Completed | Merck Sharp & Dohme LLC | 352 | 2023-11-08 | 2026-01-07 |
| A Drug-Drug Interaction Study of MK 8527 With a Combined Oral Contraceptive (LNG/EE) MK-8527, LNG/EE - Human Immunodeficiency Virus (HIV), HIV Pre-Exposure Prophylaxis | Phase 1 | Completed | Merck Sharp & Dohme LLC | 14 | 2023-08-14 | 2025-01-20 |
| MK-8527 Single-Dose Trial in HIV-1 Infected Participants (MK-8527-004) MK-8527 - Human Immunodeficiency Virus | Phase 1 | Completed | Merck Sharp & Dohme LLC | 20 | 2022-11-17 | 2025-03-26 |
| A Study of MK-8527 in Human Immunodeficiency Type 1 Virus (HIV-1) Infected Participants (MK-8527-002) MK-8527 - Human Immunodeficiency Virus, AIDS Virus | Phase 1 | Completed | Merck Sharp & Dohme LLC | 17 | 2019-02-11 | 2020-09-28 |
Acquired Immunodeficiency Syndrome (6) · Renal Insufficiency (1)
United States (11) · South Africa (4) · Kenya (2) · Romania (2) · Argentina (1) · Brazil (1) · Chile (1) · Colombia (1) · Dominican Republic (1) · France (1) · Guatemala (1) · Israel (1) · Malaysia (1) · Peru (1) · Philippines (1)
2018 (1), 2023 (1), 2025 (1)